Last reviewed 2026-04-20 · How we verify

GNRH-A Triptorelin

At a glance

Approved indications

No approved indications tracked.

Common side effects

• Hot flashes/flushes
• Pain - Joint
• Fatigue (asthenia, lethargy, malaise)
• Insomnia
• Sweating (diaphoresis)
• Injection site pain
• Vaginal dryness
• Mood alteration - depression
• Libido
• Nausea
• Osteoporosis
• Pain - Vagina

Key clinical trials

• Exploration of Treatment Effect of Novel Hormone Therapy Combined With Local Treatment Based on PSMA PET/CT Evaluation in mHSCP Patients (PHASE2)
• Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study (PHASE3)
• Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers (PHASE2, PHASE3)
• Radiotherapy After Prostatectomy for Node Positive Prostate Cancer (PHASE3)
• Refining Fertility-sparing Treatment in Endometrial Carcinoma Based on Molecular Classification (PHASE2, PHASE3)
• A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer (PHASE3)
• Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response (PHASE2)
• A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.